SCHEMBL19902573

SCHEMBL19902573

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cccc(-c2cc[nH]n2)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.43
PARP1 P09874 2/20 0.42
LRRK2 Q5S007 1/20 0.42
MAPK14 Q16539 3/20 0.41
NPC1 O15118 2/20 0.41
MAP3K5 Q99683 1/20 0.41
PDE4B Q07343 3/20 0.40
ROCK2 O75116 2/20 0.39
ROCK1 Q13464 1/20 0.39
MLLT3 P42568 1/20 0.39
MLLT1 Q03111 1/20 0.39
MAPK10 P53779 1/20 0.39
BRD4 O60885 1/20 0.39
ATR Q13535 1/20 0.38
PDE10A Q9Y233 1/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902577 0.90 NPC1 (0.44) MAPK8NPC1ROCK2ROCK1ATR
SCHEMBL17452894 0.88 ROCK2 (0.53) MAPK8PARP1LRRK2MAPK14MAP3K5
SCHEMBL20229915 0.87 ROCK2 (0.51) MAPK8MAPK14MAP3K5PDE4BROCK2
SCHEMBL19902381 0.85 MAPK14 (0.42) MAPK8PARP1LRRK2MAPK14NPC1
SCHEMBL19902632 0.81 KMT2A (0.51) PARP1NPC1ROCK2ROCK1MEN1
SCHEMBL19902704 0.81 MAP3K5 (0.41) MAPK8PARP1LRRK2MAPK14MAP3K5
SCHEMBL17452871 0.79 ROCK2 (0.54) MAPK8NPC1ROCK2ROCK1MEN1
SCHEMBL19902640 0.78 ROCK2 (0.48) NPC1ROCK2ROCK1MEN1RAB9A
SCHEMBL19902696 0.77 NPC1 (0.50) NPC1MAP3K5ROCK2ROCK1BRD4
SCHEMBL19902383 0.77 CYP1A2 (0.48) MAPK14NPC1ROCK2MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 MAPK8 468/4885PARP1 1915/4885LRRK2 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.